The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...

CSL Behring has made a name for itself manufacturing biologics and plasma, but its unveiling of a new R&D site—slated to be the company’s largest—is evidence of expanded development efforts. The new ...

KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that ...

SAN FRANCISCO--(BUSINESS WIRE)--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage points, according to ...

– Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein ...

HEMGENIX ® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years ...

The FDA has accepted CSL Behring’s priority review application for a hemophilia B gene therapy, potentially fast-tracking the drug after a bumpy ride that included a clinical hold—and later, a lift.

- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...

- TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Hemgenix will have a list price ...

KING OF PRUSSIA, Pa., May 6, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) ...